Acquire Abatacept Comparison of Sub(qu)cutaneous VS. Intravenous In Inadequate Responders To Methotrexate Trademark Details

This mark is alive with a status of First Extension - Granted. The last case file activity for this mark occured 6 years ago on Wednesday, June 22, 2016, according to the United State Patent & Trademark Office
Word Mark Acquire Abatacept Comparison of Sub(Qu)Cutaneous Vs. Intravenous in Inadequate Responders to Methotrexate
Status Alive 730 — First Extension - Granted

Current Owner

Bristol-Myers Squibb Company of New York, NY

View all trademarks for Bristol-Myers Squibb Company
Other Trademarks for Bristol-Myers Squibb Company
Serial Number 86437926
Status Date Wednesday, June 22, 2016
Filing Date Wednesday, June 22, 2016
Attorney Marilyn F. Kelly

Correspondent

MARILYN F. KELLY
Bristol-Myers Squibb Company
PO Box 4000
Fort Dix, NJ 08640-0902

Case File Statements

Disclaimer with Predetermined Text "Abatacept Comparison of Sub(Qu)Cutaneous Vs. Intravenous in Inadequate Responders to Methotrexate"
Goods & Services Providing medical and scientific research information in the field of pharmaceuticals and clinical trials

Classifications

International Class Codes
042 — Class 42 includes mainly services provided by persons, individually or collectively, in relation to the theoretical and practical aspects of complex fields of activities; such services are provided by members of professions such as chemists, physicists, engineers, computer programmers, etc.
U.S. Class Codes 100, 101
Status 6 — Active
Status Date Friday, November 7, 2014
Primary Code 042

You must be signed in to print.

Once signed in, look for the PDF button.